ISRCTN82277382
Completed
未知
Safety and immunogenicity of concomitant administration of a virosomal hepatitis A vaccine (Epaxal®) with DTP, aHib, IPV, OPV and MMR vaccines versus non-concomitant administration in 12 to 15 month-old children
Berna Biotech Ltd (Switzerland)0 sites322 target enrollmentMarch 10, 2006
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Berna Biotech Ltd (Switzerland)
- Enrollment
- 322
- Status
- Completed
- Last Updated
- 5 years ago
Overview
Brief Summary
2007 results in https://pubmed.ncbi.nlm.nih.gov/17721372/ (added 11/01/2021)
Investigators
Eligibility Criteria
Inclusion Criteria
- •Healthy children between 12 and 15 months old at the time of vaccination
Exclusion Criteria
- •1\. Children that have not received three documented doses of DTP, aHib and polio vaccines during infancy
- •2\. Children that have received a documented dose of MMR during infancy
- •3\. Previous vaccination against hepatitis A
- •4\. Any confirmed or suspected immunosuppressive or immunodeficient condition
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Concomitant administration of the Novavax vaccine and a 20-valent pneumococcal conjugate vaccine in adults aged =60 yearsVaccination is a key strategy for preventing respiratory illnesses. Pneumococcal vaccination is recommended for all adults (age >60 years). Given their wide application, co-administration of pneumococcal and Covid-19 vaccines may support broad population-wide coverage. However, it is unclear whether the co-administration of the new, Omicron-adapted Novavax (NVX XBB.1.5) vaccine and a 20-valent pneumococcal conjugate vaccine results in lower immunogenicity than the administration of either alone.Therapeutic area: Body processes [G] - Immune system processes [G12]EUCTR2022-004118-12-ATMedical University of Vienna256
Active, not recruiting
Not Applicable
Safety and immunogenicity of concomitant vaccination with IC51 and Havrix 1440 in healthy subjects. A single-blind randomised, controlled phase 3 study.EUCTR2005-003526-25-DEIntercell AG192
Completed
Phase 1
A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of rgp120/HIV-1MN (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy Adults.HIV InfectionsNCT00001044National Institute of Allergy and Infectious Diseases (NIAID)80
Completed
Not Applicable
Mixing of the COVID-19 vaccines Covishield and Covaxin for safety assessmentCOVID-19 (SARS-CoV-2 infection)Infections and InfestationsISRCTN98052401Asian Healthcare Foundation44
Completed
Phase 4
Immunogenicity and Safety of Concomitant Administration of Bivalent COVID-19 Vaccines With Influenza VaccinesImmune ResponseSafetyNCT05970887Catholic Kwandong University154